Friday, 15 Nov 2019

You are here

Patient Reluctance to Take Bisphosphonates

The NY Times reports that millions of Americans with osteoporosis are driven to stop or not take bisphosphonate therapies over the fear of exceedingly rare side effects - osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF).

Patient and physician reaction to these rare reports have resulted in a 50 percent decrease in these drugs from 2008 to 2012, and the trend continues.

Osteoporosis leaders have voiced their concern over the inappropriate reactions to ONJ and AFF, such that the American Society for Bone and Mineral Research, the National Osteoporosis Foundation and the National Bone Health Alliance have all put out an urgent call for doctors to be more aggressive in treating patients at high risk for fracture and calling for better education of patients.  Nonetheless, many physicians note that many patients won't go on these agents and many of those who are on bisphonsphonates wish to stop.

Dr. Paul Miller has recently written that "the benefit/risk ratio of bisphosphonates reducing all fracture risk vs the potential for the development of an atypical sub-trochanteric femur fracture is exceedingly in favor of bisphosphonate use in higher risk populations." (Citation source http://buff.ly/1U2hngr)

The estimated risk of AFF with bisphosphonates is 10 to 40 events per 100,000 users. Fewer than one in 100,000 have had the ONJ.

Drs. Black and Rosen have recently written in the NEJM (http://buff.ly/1TSOfu2) that you need to treat 50 people to prevent a fracture, but you need to treat 40,000 to see an atypical fracture.

Clearly there is a dire need for better education of clinicians and patients on the benefits and risks of treating osteoporosis, especially those who are assessed to have a high risk of fracture.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Physical Activity Lowers Fracture Risk in Post-Menopausal Women

An analysis from the Women’s Health Initiative study shows that postmenopausal women who participate in vigorous physical activity have a statistically lower risk of total and site-specific fractures

High Dose Statins Increase Odds of Osteoporosis

It is unknown if inhibiting cholesterol synthesis (with statins) might influence sex-hormone production and therefore, the risk of osteoporosis. A new study shows that, in statin-treated individuals, the development of osteoporosis is statin dose-dependent.

Sprifermin Benefits Cartilage Loss but not Symptoms in Knee Osteoarthritis

Intra-articular sprifermin given to patients with symptomatic and radiographic knee osteoarthritis has been shown to significantly improve total femorotibial joint cartilage thickness after 2 years, but without significant clinical benefits. Which begs the question, why is there a disconnect between radiographic disease modification (cartilage thickness) and symptomatic improvement?

Bisphosphonates and the Risk of Osteonecrosis of the Jaw

Even though oral bisphosphonates are widely used, there is an inordinate concern over the risk of osteonecrosis of the jaw (ONJ). A new UK study suggests that the risk of ONJ is elevated six fold by the use of biphosphonates.

ASBMR Recommendations on Secondary Fracture Prevention

The American Society for Bone and Mineral Research has developed multistakeholder consensus clinical recommendations for the prevention of secondary fractures for those aged 65 years and older after an initial hip or vertebral fracture.

Overall they have promoted 13 recommendations (7 primary and 6 secondary) strongly supported medical evidence.

Highlights include recommendations for: